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ABSTRACT: During human heart failure, the balance of cardiac energy use switches from predominantly fatty
acids (FAs) to glucose. We hypothesized that this substrate shift was the result of mitochondrial degeneration;
therefore, we examined mitochondrial oxidation and ultrastructure in the failing human heart by using respi-
rometry, transmission electronmicroscopy, and gene expression studies of demographicallymatched donor and
failing human heart left ventricular (LV) tissues. Surprisingly, respiratory capacities for failing LV isolated
mitochondria (n=9)were not significantly diminished comparedwith donorLV isolatedmitochondria (n=7) for
glycolysis (pyruvate + malate)- or FA (palmitoylcarnitine)-derived substrates, and mitochondrial densities,
assessedvia citrate synthase activity,were consistent betweengroups.Transmission electronmicroscopy images
also showed no ultrastructural remodeling for failing vs. donor mitochondria; however, the fraction of lipid
droplets (LDs) in direct contact with amitochondrionwas reduced, and the average distance between an LD and
its nearest neighboringmitochondrionwas increased.Analysis of FAprocessinggene expressionbetweendonor
and failing LVs revealed 0.64-fold reduced transcript levels for the mitochondrial-LD tether, perilipin 5, in the
failing myocardium (P = 0.003). Thus, reduced FA use in heart failure may result from improper delivery,
potentially via decreased perilipin 5 expression and mitochondrial-LD tethering, and not from intrinsic mito-
chondrial dysfunction.—Holzem, K. M., Vinnakota, K. C., Ravikumar, V. K., Madden, E. J., Ewald, G. A.,
Dikranian, K., Beard, D. A., Efimov, I. R. Mitochondrial structure and function are not different between
nonfailing donor and end-stage failing human hearts. FASEB J. 30, 2698–2707 (2016). www.fasebj.org
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Heart failure (HF) is the end stageofmanycardiovascular
diseases, in which hypertrophic remodeling no longer
meets cardiac output demand. The burden of HF has
reached epidemic proportions, with .20 million people
affected worldwide (1). During the progression to HF,
the heart switches energy substrate use from preferen-
tial utilization of fatty acids (FAs) to greater glucose
consumption (2). Although glucose is a more efficient
oxidative substrate forATPsynthesis, theheart is not able
to compensate for ATP demand, and this state of limited
energy supplymay contribute to disease pathogenesis (3,
4). In addition, mitochondrial respiratory dysfunction
has been reported in animal models of HF (5, 6), but re-
spiratory studies in the failing human heart have yielded
inconsistent results (7–11). Mitochondrial degeneration
has also been presumed from cardiomyopathic specimen
ultrastructure, though these studies were performed
without corresponding donor specimens (12–17). Nev-
ertheless, augmenting mitochondrial function has been
considered as a therapeutic strategy for HF (18, 19).
We hypothesized that asymmetrically impaired
mitochondrial respiratory capacity contributes to sub-
strate utilization shift in the failing human heart; there-
fore, we anticipated reductions in oxidative respiration,
with a greater defect in FA vs. glycolytic substrate re-
spiratory capacity. We assessed respiration rates for the
glycolysis-derived substrate, pyruvate + malate (PM),
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and FA-derived substrate, palmitoylcarnitine (PC), in
isolated mitochondria from both human donor and
failing left ventricular (LV) tissue. We also predicted
that respiratory impairment in failing heart mitochon-
dria would be associated with mitochondrial structural
deterioration, assessed by transmission electron mi-
croscopy (TEM).
Contrary to our expectations, we found neither
functional nor structural alterations in failing heart
mitochondria. Thus, we proceeded to investigate energy
substrate handling preceding mitochondrial use. By us-
ing TEM image analysis, we quantified mitochondrial–
lipid droplet (LD) coupling and found that the fraction of
LDs in direct contact with mitochondria was reduced in
failure. In addition, we examined the expression of sev-
eral genes that are important for FA processing and
found that expression of perilipin 5 (PLIN5), which
regulates LD tethering to mitochondria, is reduced in
HF. Taken together, our findings suggest that metabolic
remodeling of energy substrate utilization in human HF
is not the result of intrinsic mitochondrial functional or
structural degeneration. Instead, our ultrastructural and
gene expression data support the theory that FAdelivery
to mitochondria may be impaired. These findings have
important implications for therapeutic strategies to sup-
port metabolism in failing human myocardium.
MATERIALS AND METHODS
Human heart recovery and clinical data
All studies using human heart tissue have been approved by
the institutional review board at Washington University
School of Medicine. We recovered donor human hearts that
were rejected for transplantation from the Mid-America
Transplant Services (St. Louis, MO, USA), and end-stage
failing hearts from transplantation recipients at Barnes-
Jewish Hospital (St. Louis, MO, USA). In total, all studies
(respiration, TEM, and gene expression) used 34 donor and
39 failing hearts. All hearts were explanted by a cardiotho-
racic surgeon and were rapidly transferred to a member of
the research team in the operating room (OR). Coronary ar-
tery perfusion with ice-cold cardioplegic solution (110 mM
NaCl, 1.2 mMCaCl2, 16.0 mMKCl, 16.0 mMMgCl2, and 10.0
NaHCO3) was used to arrest hearts. Heartswere then packed
in a cooler with cold cardioplegic solution to be transported
to the laboratory (with a total time from heart excision to
laboratory of ;20 min). After arrival, hearts were unpacked
and placed in a tray with additional ice-cold cardioplegic
solution for dissection. Before mitochondrial isolation, LV
tissue was rapidly collected and preserved in RNA later
(Sigma-Aldrich, St. Louis, MO, USA) for mRNA or flash-
frozen in liquid nitrogen for enzymatic analysis. Tissue
specimens for mitochondrial isolation were then dissected
within 10 min from heart unpacking.
Clinical data for donor hearts were collected from Mid-
America Transplant Services consent packets. Measurements of
donor heart cardiovascular disease and function were obtained
from clinical assessments that were conducted while evaluat-
ing the organ for donation, such as echocardiograms, coronary
angiographs, and electrocardiograms. Failing heart clinical in-
formation was provided by the Translational Cardiovascular
Biobank & Repository at Washington University School of
Medicine,whichwereprocured from theBarnes-JewishHospital
electronic medical record and provided to the laboratory in a
deidentified manner (Table 1 and Supplemental Unit 1).
Mitochondrial isolation and
respiration measurements
All reagents and tools for mitochondrial isolation were
prepared before attending theOR for recovery. During heart
dissection, a transmural LV specimen ;2–4 g was dissected
from the anterior free wall (Fig. 1A) and epicardial fat was
excised. Tissue was then finely minced and homogenized at
4°C in a buffer that contained 200 mM mannitol, 50 mM
sucrose, 5mMKH2PO4, 5 mMMOPS, 1mMEGTA, and 0.1%
bovine serum albumin (pH 7.15), with 5 U/ml Bacillus
licheniformis protease. Mitochondria were isolated through
differential centrifugation, as previously described (20),
and protein was quantified by bicinchoninic acid assay
(Thermo Fisher Scientific Life Sciences, Waltham, MA, USA).
Respiration measurements were conducted by using an
Oxygraph-O2k high-resolution respirometer (Oroboros,
Innsbruck, Austria) in buffer that contained 130 mM KCl,
2.5 mM K2HPO4, 20 mM MOPS, 1 mM EGTA, and 0.1%
bovine serum albumin (pH 7.15). For our respiration pro-
tocol (Fig. 1B), we first injected 0.1 mg protein from the
mitochondrial sample. After 70 s, substrate was added, with
either PM (10 mM/2 mM) or PC (25 mM) to determine S2
respiration before ADP addition. At 110 s after substrate
injection, ADP (350 mM) was added to establish S3 respira-
tion, and the experiment was continued through to S4.
Mitochondrial enzyme activity measurement
Citrate synthase (CS) enzymatic activities were measured
by spectrophotometry, and specific activities were mea-
sured during the linear phase with the changing absorbance
(l, 232 nm) of the reaction product between CoA-SH and
2-nitrobenzoic acid (protocol distributed by Oroboros). To nor-
malize respiration data, all enzyme assays were conducted by
using samples from the same hearts from which respiration
data were collected.
TEM sample preparation and imaging
Specimens were dissected surrounding an LV coronary artery,
whichwas cannulated, andmajor leakingbrancheswere sutured
shut. Tissue was then perfused with 2% glutaraldehyde in
0.1 M sodium cacodylate. Specimens were postfixed in 1%
osmium tetroxide, dehydrated, cleared in toluene, and embed-
ded in araldite resin. Ultrathin sections (70–80 nm) were cut
with an Ultracut UCT ultramicrotome (Leica Microsystems, Buf-
faloGrove, IL, USA) andweremounted on Formvar coatedmesh
grids. Sections were counterstained with saturated ethanolic
uranyl acetate, followed by lead citrate.
Imageswere acquired on a Jeol 100B (Jeol, Tokyo, Japan) by
a separate investigator, whowas blinded to the donor/failing
status of the specimens. Five different regions per heart were
randomly selected for an overview image (33000), and 10
nonoverlapping analysis images (38000) were acquired from
within the overview region. Images were processed by using
Fiji software (http://fiji.sc/). All mitochondria and LDs from
images were measured (totaling ;800–2500 mitochondria/
heart). Distances between mitochondria and LDs were com-
puted as euclidean distances between centroids. Average
mitochondrial grayscale (0–255) pixel intensities were mea-
sured and normalized to sarcomeric pixel intensities from the
same image.
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RNA isolation and real-time quantitative PCR
Total RNAwas extracted, quantified, and reverse transcribed
as previously described (21). Real-time PCR of cDNA was
performed on an Applied Biosystems 7900HT sequence de-
tector using inventoried TaqMan Gene Expression Assays for
the specific gene targets analyzed (Applied Biosystems, Foster
City, CA, USA). RPL32 was used as an endogenous control
because it is a stable reference gene for cardiac expression
studies (22).
Statistical analysis
Statistical significance was determined by unpaired, 2-tailed
Student’s orWelch’s t tests.Welch’s t test was selectedwhen an F
test revealed unequal variance between groups. Outliers were
excludedbyGrubb’s analysis.Dataarepresentedasmeans6 SEM.
A value of P, 0.05 was considered statistically significant.
RESULTS
Matched donor and failing human heart
demographics for functional
respiration measurements
Donor and failing human hearts used in our functional
studies were well matched in terms of key demographic
characteristics (Table 1). Of note, ages did not differ
between donor and failing groups, withmeans of 54.06
5.4 yr of age for donor and 52.46 3.8 yr of age for failing
groups (P = 0.81); nor were there differences in body
mass indices (BMIs), with BMIs of 26.56 1.9 kg/m2 for
donor and 26.8 6 1.6 kg/m2 for failing (P = 0.92).
Comorbidity data also demonstrate a lack of diabetes
mellitus or metabolic disease in either donor or failing
heart groups, with only 1 failing heart patient having a
history of diabetes mellitus. The ratio of males to fe-
males was similar between groups (57.1% male for
donor and 66.7% male for failing). Of importance, the
sample of donor hearts demonstrated little evidence of
cardiac disease, with only 1 heart showing LV hyper-
trophy on echocardiography.
Preserved mitochondrial respiration in
human HF
We conducted measurements in isolated mitochondria by
the protocol outlined in Fig. 1A, B. Representative O2 con-
centration and flux curves with both substrates are shown
in Fig. 1C. S2 respiration did not differ between donor and
failing mitochondria for PM or PC substrates (Fig. 2A).
We also did not observe statistically significant reductions
in absolute S3 respiratory capacity for failingmitochondria
usingPMorPC(Fig.2B),withPMO2 consumption fluxesof
195.906 19.14 and158.826 9.04nmolO2/min/mgprotein
TABLE 1. Heart groups are not different with regard to key demographic characteristics
Heart group
Demographic characteristics
Gender Age (yr) BMI (kg/m2) BMI category Comorbidities COD or Dx EF (%)
Donor
(n = 7)
F 59 20.6 Normal SH (40 y) COD: CVA
F 54 24.1 Normal HTN; LVH; SH (40 y) COD: CVA
M 27 24.5 Normal SH (13 y) COD: MVA
M 59 25.4 Overweight HTN COD: CVA
F 73 26.4 Overweight SH (5 y) COD: anoxia
M 46 27.8 Overweight None reported COD: CVA
M 60 36.7 Obese HTN; SH ($40 y) COD: anoxia
4:3 M:F 54.0 6 5.4 26.5 6 1.9 3:4, BMI , 24.9:
BMI $ 24.9
CV: 3 HTN; 1
LVH; 5 SH
COD: 2 anoxia;
4 CVA; 1 MVA
Failing
(n = 9)
M 47 18.4 Underweight MI/CAD; PH Dx: ICM 30
M 47 21 Normal PH Dx: NICM 15
F 61 24.8 Normal COPD; hypothyroidism;
KD; OSA; PH
Dx: NICM ,20
M 32 26 Overweight Becker’s MD; PH Dx: NICM NA
F 65 28 Overweight Myocarditis; PH Dx: NICM 45
F 51 28.2 Overweight PH; SH Dx: NICM 22
M 63 29.4 Overweight DM; MI/CAD;
MR; PH; SH
Dx: NICM 20
M 63 31.8 Obese MI/CAD; PH Dx: ICM 35
M 43 33.2 Obese Cirrhosis; KD; PH Dx: NICM 50
2:1 M:F 52.4 6 3.8 26.8 6 1.6 1:2, BMI , 24.9:
BMI $ 24.9
CV: 1 DM; 1 MD;
2 MI/CAD; 1 MR;
1; myocarditis;
9 PH; 2 SH
Dx: 2 ICM;
7 NICM
29.6 6 4.5
Of note, the comorbidity information shows a lack of dm for both heart groups, and the donor hearts demonstrate little evidence of
cardiac disease. Data are presented as means 6 SEM. cad, coronary artery disease; cod, cause of death; copd, chronic obstructive pulmonary
disease; cva, cerebrovascular accident (stroke); dm, diabetes mellitus; dx, diagnosis; ef, ejection fraction; htn, hypertension; kd, kidney
disease; lvh, lv hypertrophy; md, muscular dystrophy; mi, myocardial infarction; mr, mitral regurgitation; mva, motor vehicle accident;
na, not available; osa, obstructive sleep apnea; ph, pulmonary hypertension; sh, smoking history. The text in italic is a summary of the data
in table.
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(P = 0.12) and PC O2 consumption fluxes of 122.506 23.01
and 91.926 14.42 nmol O2/min/mg protein (P = 0.19) for
donor and failing hearts, respectively. In addition, there
were no differences between donor and failing mitochon-
dria in S4 respiration for either PM or PC (Fig. 2C). Our
summary results also demonstrate that S3/S4 or S3/S2 re-
spiratory control ratios were not different between do-
nor and failing heartmitochondria for either PM (S3/S4 =
6.096 1.73 vs. 4.866 0.98,P= 0.45, and S3/S2 = 25.46 6.9
vs. 17.7 6 2.2, P = 0.24) or PC (S3/S4 = 5.23 6 1.32 vs.
4.04 6 0.57, P = 0.47, and S3/S2 = 17.8 6 7.4 vs. 9.1 6
0.9, P = 0.20, Fig. 2D, E). To ensure consistent mito-
chondrial content between heart groups,we assayedCS
from the same hearts used for respiration studies, and
CS-specific activities were not different per g muscle
tissue between donor and failing hearts (14.5 6 2.4 vs.
14.7 6 1.8 U/g tissue; P = 0.92; Fig. 2F).
No ultrastructural differences between donor
and failing heart mitochondria
We proceeded to examine whether there were ultra-
structural differences between donor and failing heart
mitochondria. Becausewe recovered intact human hearts
immediately upon excision in the OR, we conducted
fixation by coronary perfusion (Fig. 3A–C, schematic),
which enabled high-quality TEM image results. Exam-
ples of overview region images (magnification,33000)
are displayed with nonoverlapping image regions
(magnification, 38000) used for quantification for do-
nor hearts (Fig. 3D, F) and failing hearts (Fig. 3G–I).
Representative zoomed-in images of individual mito-
chondria are shown from each of 4 separate donor and
failing hearts (Fig. 4A, B), which highlights that donor
and failing heart mitochondria appear similar in size
and demonstrate dense cristae packing. Further TEM
myocardial images from each donor and failing heart
used for ultrastructural analysis are shown in Supple-
mental Unit 2, along with the ultrastructure of example
isolated mitochondria (Supplemental Unit 3).
We measured cross-sectional area for each mito-
chondrion and quantified cristae density by using
average grayscale pixel intensities (0–255), normalized
to sarcomeric pixel intensity for each image. Because
we measured hundreds of mitochondria per heart, we
analyzed frequency distribution data with LOWESS
Figure 1. A) Representative image of a donor human heart, with dashed box indicating the mitochondrial isolation region. B)
Mitochondrial respiration measurement protocol and example O2 concentration and ﬂux curves. C) Representative PM and PC O2
concentration and ﬂux curves for donor and failing hearts. A, aorta; PA, pulmonary artery; RA, right atrium; RV, right ventricle.
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regression curves. Figure 4C–F shows LOWESS curves
of mitochondrial cross-sectional area and average pixel
intensity from mitochondrial counts and percentages of
total, respectively, for each donor and failing heart.
When averaging results, mitochondrial area was not
different betweendonor and failing human hearts (2.663
1056 0.323 105 vs. 2.873 1056 0.313 105 nm2; P = 0.65;
Fig. 4G). In addition, average mitochondrial pixel in-
tensities were 92.16 4.7 for donor mitochondria compared
with 97.66 4.6 for failing heart mitochondria (P = 0.42;
Fig. 4H), which indicated no differences in cristae pack-
ing within mitochondria.
Impairment of mitochondria-LD tethering and
FA substrate delivery
Given the lack functional or architectural disruptionwithin
failing human heart mitochondria, we examined whether
impairment in FA processing precedes mitochondrial
uptake. From ultrastructural images, we assessed the
physical association of mitochondria with LDs. Most
LDs were in direct contact with $1 mitochondria in
both donor and failing hearts; however, there were
more isolatedLDs in the failingmyocardium. InFig. 5A,
B, example TEM images show an LD in direct associa-
tion with mitochondria in donor myocardium and an
isolated LD in the failing heart. We counted LD-
mitochondrial interactions and found the percentage
of LDs in direct mitochondrial contact was reduced in
failing hearts compared with donor hearts (74.1 6 1.3
vs. 83.26 3.7%; P = 0.025; Fig. 5C). In addition, average
euclidean distance from an LD to its nearest neighbor-
ing mitochondrion was correspondingly increased,
with distances of 833.0 6 56.0 and 597.9 6 51.3 nm for
failing and donor hearts, respectively (P = 0.020; Fig.
5D). There were no differences in overall LD density
between donor and failing hearts, though there was a
trend toward increased LD density for failing hearts
with nonischemic cardiomyopathy (NICM; Supple-
mental Unit 4).
We then examined expression of genes that are im-
portant for FA processing outside of mitochondria. We
assessed transcript levels for genes that encode adipose
triglyceride lipase (ATGL, encoded by PNPLA2), cluster
of differentiation 36 (CD36, encoded by CD36), lipo-
protein lipase (LPL, encoded by LPL), PLIN5 (encoded
by PLIN5), peroxisome proliferator-activated receptor
a (PPARa, encoded by PPARA), and PPARg (encoded
by PPARG). In a large sample of donor and failing hu-
man LV specimens, we identified PLIN5 as having 0.64-
fold reduced expression in failure (P = 0.003; Fig. 5E),
and PLIN5 protein is known to be important for LD
packaging and tethering to mitochondria (23, 24). We
also found expression of LPL to be up-regulated by
54.3% in failing LV tissues compared with donor LV
tissues (P = 0.021; Fig. 5E). None of the other FA pro-
cessing genes we examined were significantly altered in
failing human LV (Fig. 5E). Expression of NPPA, which
encodes the atrial natriuretic peptide, was increased
(3.2-fold; P = 0.073), and expression of MYH6, which
encodes a-myosin heavy chain, was decreased (0.17-
fold; P = 2.4E-5) in failing hearts compared with donor
hearts, as expected (Fig. 5F).
Figure 2. A–C) Average S2 (A), S3 (B), and S4 (C) respirations with PM and PC substrates for donor hearts (n = 7) and failing
hearts (n = 9). D, E) S3/4 (D) and S3/2 (E) respiratory control ratios (RCRs) for donor hearts (n = 7) and failing hearts (n = 9).
There were no statistically signiﬁcant differences between donor and failing hearts for respiration rates or RCRs with either
substrate. F) CS-speciﬁc activities/g muscle tissue were not different between donor hearts (n = 7) and failing hearts (n = 9). Data
are expressed as means 6 SEM.
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DISCUSSION
Contrary to our hypothesis, our results demonstrate a lack
ofmitochondrialoxidativedysfunction forbothglycolysis-
and FA-derived substrates in mitochondria isolated
from failing human hearts. Furthermore, TEM images of
perfusion-fixed human LV myocardium reveal that mi-
tochondria show preserved structure. Instead, our results
support the theory that FA delivery to mitochondria
may be impaired. Our TEM images reveal reduced LD-
mitochondrial coupling and increased distances between
LDs and mitochondria in failure. We also show that the
transcript level for the mitochondrial-LD tether, PLIN5, is
reduced in failing hearts, which may diminish the efficient
couplingofmitochondria to lipid stores and impair lipolysis.
Studies that suggest mitochondrial
remodeling in HF
Our findings contradict results fromseveral animalmodel
studies of HF, which suggest that mitochondrial respira-
tion is impaired (5, 6). For human HF, some studies have
suggested mitochondrial dysfunction solely on the basis
of enzymatic activities (19, 25), whereas previous reports
on mitochondrial respiration in human HF have pro-
duced inconsistent results (7, 8). In a report by Sharov
et al. (7), PM-stimulated respiration was reduced but mi-
tochondrial density in donor vs. failing hearts was not
measured. In addition, although Cordero-Reyes et al. (8)
analyzed a large number of failing heart samples, their
comparisongroup consisted of a small numberofpatients
with right ventricular failure,which limited their power to
detectadifferencebetweengroups.Becauseweconducted
studies with a relatively large sample of well-matched
donor hearts, our investigation provides stronger evi-
dence for lack of respiratory impairment in mitochon-
dria from failing human hearts.
In addition, there have been several classic studies on
mitochondrial architecture within the diseased human
myocardium (12, 16, 26, 27). The majority of these studies
were conducted by using cardiomyopathic specimens
collected via biopsy during surgery. Fixation by diffusion
into suchspecimens couldbe incomplete andmay result in
mitochondrial structural artifacts.Moreover, these studies
wereperformedwithout correspondingdonor specimens;
thus, it cannot be determined whether the observed mi-
tochondrial abnormalitieswere the result of true structural
alterations or artifacts of preservation. In contrast, we re-
covered both donor and failing freshly isolated hearts,
which we perfused for optimal fixation.
Age-related muscle dysfunction unrelated to
mitochondrial impairment
Debate regarding the causal role of mitochondrial abnor-
malities inmuscle dysfunction is not limited toHF. Similar
contradictory studies have been published regarding hu-
man age-related muscle performance. Perhaps even more
appealing than in HF, for which there is a clear extrinsic
trigger for disease, is the mitochondrial theory of aging,
in which progressive declines in mitochondrial func-
tion could promote muscular deterioration (28, 29). Some
studies have demonstrated a relationship between im-
paired mitochondrial function and age in human skeletal
muscle, whereas others have not found any changes with
age (30–33). However, similar to our study, when large
numbers of human donor and diseased specimens were
analyzed, biologically and statistically significant mito-
chondrial differences were not apparent (34).
Figure 3. A–C) Illustrated schematic for TEM sample preser-
vation. A) A portion of the LV surrounding a coronary artery
was dissected and cannulated. Tissue was then perfused with
ﬁxative for optimal preservation. A small core of tissue was
then excised (B) and stored in ﬁxative (C). D–I) Represen-
tative electron micrographs from donor (D–F) and failing
(G–I) heart muscle. D, G) Overview images; red and blue
boxes outline nonoverlapping regions for donor hearts (E, F)
and for failing hearts (H, I). Original magniﬁcation, 33000
(D, G) and 38000 (E, F, H, I) Scale bar, 1 mm.
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Isolated mitochondria vs.
permeabilized fibers
Mitochondrial isolation yields range from 20–40% of initial
mitochondria,which potentially leads to selection bias, and
respiration measurements can differ between isolated mi-
tochondria and permeabilized fiber preparations (35, 36).
These findings suggest that mitochondrial isolation leads
to apparent respiratory dysfunction in diseased tissues;
however, our results show no respiratory dysfunction fail-
ing isolated mitochondria, which is inconsistent with se-
lection for dysfunctional mitochondria. Furthermore, the
method of massing tissue before isolation to compute the
fractionofmitochondrial recoverywouldbe inaccurate and
inappropriate for the human heart as a result of disparate
amounts of fibrosis between donor and failing hearts. In
human heart, the amount of fibrosis has been estimated at
6–11% in the normal heart and#35% in disease (37).
Figure 4. A, B) Representative zoomed-in images of individual mitochondria from 4 separate donor (A) donor and failing (B)
hearts. C–F). Frequency distribution LOWESS curves for each individual heart expressed by count (C, D) and by percentage of
total (E, F) for mitochondrial area (C, E) and pixel intensity (D, F). G, H) Pooled mitochondrial area (G) and pixel intensity (H),
with individual heart data points, show no differences between donor hearts (n = 5) and failing hearts (n = 6). Data are expressed
as means 6 SEM. Scale bar, 500 nm.
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FA use gene remodeling in human HF
In this study,weexamined the expressionof several genes
that encode for proteins that are important for FA pro-
cessing, includingATGL,CD36,LPL,PLIN5,PPARa, and
PPARg. Of these, we found significant down-regulation
of PLIN5 and up-regulation of LPL. Increased expression
of LPL in the setting of HF is surprising, as it would be
expected to enhance lipid uptake (38). However, altered
expression of PLIN5 in the mouse heart disrupts LD lo-
calization and cardiac substrate use (39, 40), and in rat
muscle, PLIN5 overexpression leads to bettermatching of
FA supply to oxidative metabolism (41). Recently, PLIN5
has been shown to be regulated by PKA, with phos-
phorylation promoting ATGL activation and increased
LDbreakdown (42, 43),which indicates thatPLIN5down-
regulationmaybe sufficient to limit FAcatabolism.PLIN5
also facilitates docking of other lipolytic proteins, which
can promote cardiac dysfunctionwhen altered (39). Thus,
reduced PLIN5 expression in human HFmay disrupt LD
dynamics, localization, and lipolysis.
We previously investigated energy substrate pro-
cessing genes and found altered expression of SLC27A4
and PDK4 in humanHF (21). SLC27A4 encodes the long-
chain fatty acid transport protein 4 (FATP4), which
regulates cellular FA uptake (44). SLC27A4 was down-
regulated inHF,which could potentially decrease cardiac
FA transport. PDK4 encodes pyruvate dehydrogenase
kinase 4 (PDK4) and its expression was increased in fail-
ing myocardium. PDK4 inhibits pyruvate dehydrogenase
via phosphorylation, and pyruvate dehydrogenase gov-
erns the balance between cardiac glucose and FA use by
bridging glycolysis with the tricarboxylic acid cycle (45).
Thus, increased PDK4 might be expected to reduce glu-
cose and enhance FA use, but PDK4 regulation could
potentially be a compensatorymechanism resulting from
Figure 5. A, B) Representative
electron micrographs showing
an LD in contact with mito-
chondria in donor heart (A) and
an isolated LD in failing heart
(B). Asterisks indicate LDs; ar-
rowheads indicate LD-mitochon-
drial coupling. C, D) Percent of
LDs in direct mitochondrial con-
tact (C) and euclidean distance
between LD centroid and near-
est mitochondrial centroid (D)
for donor hearts (n = 5) and
failing hearts (n = 6). E, F)
Expression levels for FA process-
ing genes (E) and NPPA and
MYH6 control genes (F) in
donor LV (n = 26) vs. failing
LV (n = 27). Data are expressed
as means 6 SEM. *P , 0.05;
**P , 0.01. Scale bar, 500 nm.
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reduced FA utilization. However, reductions in tran-
script levels for FA processing proteins, including
medium- and long-chain acyl-CoA dehydrogenases,
CD36, and carnitine palmitoyltransferase 1, have been
previously demonstrated (46, 47), although our results
contradict these data. Conversely, these studies have
also shown reduced transcript expression of GLUT1
and GLUT4, which indicates that glucose uptake may
also be inhibited in human HF. Therefore, these results
suggest global metabolic suppression of both FA and
glucose metabolism. Nevertheless, PLIN5 may not be
the only gene involved in reduced FA use in the failing
human heart, and/or, perhaps, decreased FA processing
in HF leads to altered regulation of associated genes.
Limitations
It is important to note that our nonfailing donor hearts
had been rejected for transplantation and are not normal
control human hearts. We have included detailed de-
mographic data such that the degree of disease present in
bothheartgroupscanbeconsideredwith the interpretation
of our results. Although the presence of comorbid disease
in our donor group is a limitation of our study, this is the
only means by which we can investigate pathophysiology
in ex vivo human tissue. For obvious ethical reasons, we
simply cannot use normal human heart tissue for experi-
ment; however, we have used the best possible nonfailing
human hearts available to compare with failing hearts.
Thus, our central experimental comparison is that of
nonfailing donor hearts without dysfunction to end-stage
failing heartswith severe cardiac dysfunction, and not that
of normal vs. failing hearts. Certainly, this distinction is
important by comparison to animal model investigations,
in which normal control hearts are compared with failing
hearts. The lack of differences we demonstrate between
donor and failing hearts, to some degree, may be related
to greater similarity between these groups relative to the
comparison between normal and failing animal hearts.
Inaddition,althoughinterestingworkhasbeenpublished
on differences in mitochondrial biogenesis in ischemic vs.
dilated failing hearts (19), we cannot draw ischemic cardio-
myopathy (ICM)/NICMetiology-specific conclusions inour
study.Wehadonly 2hearts each for respiration andelectron
micrographic experimentswith a primarydiagnosis of ICM;
therefore, we cannot statistically compare these with the
remaining NICM hearts, and our functional and morpho-
logic analyses are likely more reflective of NICM than of
ICM. In addition, alterations in lipid metabolism have been
well documented in cases of cardiomyopathy associated
with diabetes/obesity, but little is known about the role of
lipids in nondiabetic, nonobesity-related cardiomyopathy
(48). However, previously published work suggests that
cardiac FA storage and use may differ in patients with HF
whohaveelevatedBMIorwhoarediabetic (46, 49); thus,our
TEM studies may be impacted by factors other than HF.
CONCLUSIONS
To our knowledge, this is the first detailed study to com-
pare both the function and morphology of mitochondria
between nonfailing donor hearts and failing human hearts,
and we have demonstrated that mitochondrial respiration
and ultrastructure are surprisingly preserved in end-stage
human HF. Thus, our work strongly suggests that mito-
chondria are not the cause of metabolic remodeling in hu-
man failingmyocardium. Instead,we find reductions in the
percent of LDs directly contacting mitochondria and in
transcript levels for PLIN5, which suggest that FA use
preceding the mitochondria may be impaired. We there-
fore conclude that reduced consumption of FAs for fuel
and relatively greater glucose consumption occurs from
remodeling processes extrinsic to the mitochondria. Thus,
improved therapeutic strategies to support energy sub-
strate metabolism in HF should focus less on unimpaired
mitochondrial respiratory function and more on earlier
stages of FA processing and delivery.
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